{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Natural Product[C66892]" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT03584698: Phase 4 Interventional Completed Missed Abortion
(2019)
Source URL:
First approved in 2001
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
CanineAid by EpiCare Limited
(2010)
Source URL:
First approved in 2001
Source:
Xlear Nasal Spray by Xlear Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2025)
Source URL:
First approved in 2001
Source:
21 CFR 333E
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
WELLAGE Deep Layer Silky Facial Oil by Hugel Pharma Co.,Ltd.
Source URL:
First approved in 2001
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2010)
Source URL:
First approved in 2000
Source:
21 CFR 331
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2005)
Source URL:
First approved in 2000
Source:
M017
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Hair Loss and Scalp Moisturizing by Selenia
Source URL:
First approved in 2000
Source:
NDA210895
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02982603: Phase 4 Interventional Completed Mild Cognitive Impairment
(2015)
Source URL:
First approved in 1999
Source:
M012
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04656730: Phase 4 Interventional Completed Irritable Bowel Syndrome
(2020)
Source URL:
First approved in 1999
Source:
M012
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2011)
Source URL:
First approved in 1998
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE